{"entity":{"id":"nct06382168","kind":"trial","name":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","aka":[],"tldr":"A phase 1/2 trial of Venetoclax in acute myeloid leukaemia, run by Delta-Fly Pharma, Inc., now recruiting.","summary":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT06382168 by Delta-Fly Pharma, Inc., with 39 participants planned, started 2024-06-12 and due to reach its primary completion in 2026-03-31. Interventions recorded: DFP-10917 and Venetoclax.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06382168","url":"https://clinicaltrials.gov/study/NCT06382168"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":["bcl2-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["venetoclax"],"companies":["delta-fly-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06382168","phase":"1/2","setting":"Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","sponsor":"Delta-Fly Pharma, Inc.","started":"2024-06-12","startedType":"actual","enrolled":39,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06382168/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/"}]}}